Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial

Titus F M Wijnands, Tom J G Gevers, Leo J Schultze Kool, Joost P H Drenth, Titus F M Wijnands, Tom J G Gevers, Leo J Schultze Kool, Joost P H Drenth

Abstract

Background: Aspiration sclerotherapy is an effective therapeutic option for large symptomatic hepatic cysts. However, incomplete cyst reduction following aspiration sclerotherapy is frequently reported. Strong post-procedural cyst fluid secretion by cholangiocytes, which line the epithelium of the hepatic cyst, seems to be associated with lower reduction rates. Previous studies showed that somatostatin analogues curtail hepatic cyst fluid production. This trial will evaluate the effect of aspiration sclerotherapy combined with the somatostatin analogue pasireotide on cyst reduction. By combining treatment modalities we aim to improve cyst reduction leading to greater symptomatic relief and reduced rates of cyst recurrence.

Methods/design: This single center, randomized, double-blind, placebo-controlled clinical trial evaluates the additional effect of pasireotide when combined with aspiration sclerotherapy in patients with a large (>5 cm) symptomatic hepatic cyst. A total of 34 participants will be randomized in a 1:1 ratio. In the active arm, patients will receive pasireotide (long-acting release, 60 mg injection) two weeks prior to and two weeks following aspiration sclerotherapy. Patients in the control arm will receive placebo injections at corresponding intervals. The primary outcome is proportional cyst diameter reduction four weeks after aspiration sclerotherapy compared to baseline measurements, obtained by ultrasonography. As secondary outcomes, proportional volume reduction, recurrence, symptomatic relief and improvement of health-related quality of life will be assessed. Furthermore, safety and tolerability of the combination of pasireotide and aspiration sclerotherapy will be evaluated.

Discussion: This trial aims to improve efficacy of aspiration sclerotherapy by a combined approach of two treatment modalities. We hypothesize that pasireotide will decrease fluid re-accumulation after aspiration sclerotherapy, leading to effective hepatic cyst reduction and symptomatic relief.

Trials registration: This trial is registered with ClinicalTrials.gov (identifier: NCT02048319 ; registered on 6 January 2014) and EudraCT (identifier: 2013-003168-29; registered on 16 August 2013).

Figures

Figure 1
Figure 1
Study design of the SCLEROCYST trial. AS, aspiration and sclerotherapy; INJ, injection of pasireotide or placebo; Q, assessment of GIS-, PLD- and SF-36 questionnaires; US, ultrasonography.

References

    1. Gaines PA, Sampson MA. The prevalence and characterization of simple hepatic cysts by ultrasound examination. Br J Radiol. 1989;62:335–7. doi: 10.1259/0007-1285-62-736-335.
    1. Larssen TB, Rorvik J, Hoff SR, Horn A, Rosendahl K. The occurrence of asymptomatic and symptomatic simple hepatic cysts. A prospective, hospital-based study. Clin Radiol. 2005;60:1026–9. doi: 10.1016/j.crad.2005.04.011.
    1. Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol. 2003;58:626–9. doi: 10.1016/S0009-9260(03)00165-X.
    1. Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver. Hepatology. 2004;40:774–82. doi: 10.1002/hep.1840400404.
    1. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:101–8. doi: 10.1038/nrgastro.2012.254.
    1. Wijnands TF, Neijenhuis MK, Kievit W, Nevens F, Hogan MC, Torres VE, et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int. 2014;34:1578–83. doi: 10.1111/liv.12430.
    1. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology. 2010;52:2223–30. doi: 10.1002/hep.24036.
    1. Bean WJ, Rodan BA. Hepatic cysts: treatment with alcohol. AJR Am J Roentgenol. 1985;144:237–41. doi: 10.2214/ajr.144.2.237.
    1. Goldstein HM, Carlyle DR, Nelson RS. Treatment of symptomatic hepatic cyst by percutaneous instillation of Pantopaque. AJR Am J Roentgenol. 1976;127:850–3. doi: 10.2214/ajr.127.5.850.
    1. Larssen TB, Rosendahl K, Horn A, Jensen DK, Rorvik J. Single-session alcohol sclerotherapy in symptomatic benign hepatic cysts performed with a time of exposure to alcohol of 10 min: initial results. Eur Radiol. 2003;13:2627–32. doi: 10.1007/s00330-003-1923-7.
    1. Erdogan D, van Delden OM, Rauws EA, Busch OR, Lameris JS, Gouma DJ, et al. Results of percutaneous sclerotherapy and surgical treatment in patients with symptomatic simple liver cysts and polycystic liver disease. World J Gastroenterol. 2007;13:3095–100.
    1. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology. 2007;132:1104–16. doi: 10.1053/j.gastro.2006.12.039.
    1. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661–8. doi: 10.1053/j.gastro.2009.07.052.
    1. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21:1052–61. doi: 10.1681/ASN.2009121291.
    1. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol. 2010;5:783–9. doi: 10.2215/CJN.05380709.
    1. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286:69–74. doi: 10.1016/j.mce.2007.09.006.
    1. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology. 2013;58:409–21. doi: 10.1002/hep.26140.
    1. Dietrich H, Hu K, Ruffin M, Song D, Bouillaud E, Wang Y, et al. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. Eur J Endocrinol. 2012;166:821–8. doi: 10.1530/EJE-11-0773.
    1. Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103:458–65. doi: 10.1016/j.diabres.2013.12.011.
    1. Breitschaft A, Hu K, Darstein C, Ligueros-Saylan M, Jordaan P, Song D, et al. Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, Phase I, randomized, four-way crossover study. J Clin Pharmacol. 2014;54:75–86. doi: 10.1002/jcph.213.
    1. Bovenschen HJ, Janssen MJ, van Oijen MG, Laheij RJ, van Rossum LG, Jansen JB. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci. 2006;51:1509–15. doi: 10.1007/s10620-006-9120-6.
    1. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston, MA: Health Institute, New England Medical Center; 1994.
    1. Chrispijn M, Weimer FH, El-Massoudi Y, van Gulik T, Moelker A, Kool LS, et al. Treatment success of aspiration and sclerotherapy for hepatic cysts depends on cyst diameter and volume of sclerosing agent. Hepatology. 2012;56:837a–8.
    1. Benzimra J, Ronot M, Fuks D, Abdel-Rehim M, Sibert A, Farges O, et al. Hepatic cysts treated with percutaneous ethanol sclerotherapy: time to extend the indications to haemorrhagic cysts and polycystic liver disease. Eur Radiol. 2014;24:1030–8. doi: 10.1007/s00330-014-3117-x.
    1. Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014;25:18–32. doi: 10.1681/ASN.2013040398.
    1. Alvaro D, Gigliozzi A, Attili AF. Regulation and deregulation of cholangiocyte proliferation. J Hepatol. 2000;33:333–40. doi: 10.1016/S0168-8278(00)80377-3.
    1. Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology. 2013;145:65. doi: 10.1053/j.gastro.2013.04.055.
    1. Hagiwara H, Kasahara A, Hayashi N, Kono M, Suzuki K, Kashio S, et al. Successful treatment of a hepatic cyst by one-shot instillation of minocycline chloride. Gastroenterology. 1992;103:675–7.
    1. van Sonnenberg E, Wroblicka JT, D’Agostino HB, Mathieson JR, Casola G, O’Laoide R, et al. Symptomatic hepatic cysts: percutaneous drainage and sclerosis. Radiology. 1994;190:387–92. doi: 10.1148/radiology.190.2.8284385.
    1. Potthoff A, Sandkuhler F, Boozari B, Manns MP, Gebel M, Rifai K. Long-term follow up of 100 patients with polycystic liver disease - efficacy of percutaneous us-guided polidocanol sclerotherapy. J Hepatol. 2011;54:S359–9. doi: 10.1016/S0168-8278(11)60904-5.
    1. Nakaoka R, Das K, Kudo M, Chung H, Innoue T. Percutaneous aspiration and ethanolamine oleate sclerotherapy for sustained resolution of symptomatic polycystic liver disease: an initial experience. AJR Am J Roentgenol. 2009;193:1540–5. doi: 10.2214/AJR.08.1681.
    1. Jusufovic R, Zerem E. Percutaneous treatment of symptomatic non-parasitic benign liver cysts with 20% NaCl solution. Med Arh. 2011;65:35–7.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit